• Nem Talált Eredményt

18 eredmény a kulcsszóra: 'efficacy and safety'

Primary classes of compositions of numbers

The number of inverse-conjugate compositions of an odd integer n > 0 equals the number of compositions of n which are self-inverse.... We describe a bijection α between the

Protected

N/A

12
0
0
2022
A környezetvédelem alapjai

A globális környezeti kérdések és a környezetvédelem tekintetében jelentős lépés volt a Stockholmban 1972-ben megtartott konferencia, „Az Egyesült Nemzetek

Protected

N/A

246
0
0
2022
Dr. Czakó László

Randomised clinical trial: the efficacy and safety of pancreatin enteric-coated minimicrospheres (Creon 40000 MMS) in patients with pancreatic exocrine insufficiency

Protected

N/A

160
0
0
2022
Off-label use of rituximab for systemic lupus erythematosus in Europe

Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy. van Vollenhoven RF,

Protected

N/A

8
0
0
2022
A gyulladásos bélbetegségek előfordulása és kezelésének jellemzői országos felmérés alapján, valamint a kezelések lehetséges szövődményei

(2016) Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort.. (2017) Long-term

Protected

N/A

144
0
0
2022
Összefoglaló közlemény A razagilin alkalmazása Parkinson-kórban: dilemmák az idős betegek kezelése kapcsán Dr. Zádori Dénes PhD

A közepesen súlyos vagy előreha- ladott, motoros fluktuációval jellemezhető PK-os betegeken végzett PRESTO (Parkinson’s Rasagiline: Efficacy and Safety on the Treatment

Protected

N/A

4
0
0
2022
Direct Anticoagulants and Risk of Myocardial Infarction, a Multiple Treatment Network Meta-Analysis

Inclusion criteria were (1) randomized trial that assessed the clinical efficacy and/or safety of 1 or more DOAC, (2) control group including oral anticoagulation and/or

Protected

N/A

11
0
0
2022
EGFR mutation-positivelungadenocarcinoma(CEETAC):anopen-label,non-randomized,multicenter,phaseIVclinicaltrial Erlotinibassingleagentfirstlinetreatmentinlocallyadvancedormetastaticactivating RESEARCHARTICLEOpenAccess

Conclusions: Our study confirmed the efficacy and safety of first line erlotinib monotherapy in Caucasian patients with locally advanced or metastatic lung adenocarcinoma

Protected

N/A

7
0
0
2022
EGFR mutation-positivelungadenocarcinoma(CEETAC):anopen-label,non-randomized,multicenter,phaseIVclinicaltrial Erlotinibassingleagentfirstlinetreatmentinlocallyadvancedormetastaticactivating RESEARCHARTICLEOpenAccess

Conclusions: Our study confirmed the efficacy and safety of first line erlotinib monotherapy in Caucasian patients with locally advanced or metastatic lung adenocarcinoma

Protected

N/A

7
0
0
2022
Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison.

Abstract Objective The aim of this meta-analysis was to compare the efficacy and safety of infliximab-biosimilar and other available biologicals for the treatment of

Protected

N/A

14
0
0
2022
Analysis of safety and efficacy of minimal invasive pacemaker electrode repositioning

To find and develop right atrial, right ventricular and left ventricular pacemaker lead repositioning procedures which can be performed without opening of the

Protected

N/A

20
0
0
2022
ABSTRACT ApplicationofDriedHumanAmnionGrafttoImprovePost-ProstatectomyIncontinenceandPotency:ARandomizedExplorationStudyProtocol

Methods: A protocol is developed for a prospective, randomized, single-blind, single- surgeon, placebo-controlled exploration study of the efficacy and safety of dehydrated human

Protected

N/A

11
0
0
2022
Rudas Péter, DSc professor Supervisor and the member of the supervisory board: Dr

To ensure the safety, purity, efficacy and potency of the veterinary vaccines has utmost importance on account of the biological aspects of vaccines, which may affect

Protected

N/A

8
0
0
2022
ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease—An Update

A randomised, double-blind, parallel-group study to evaluate the safety and efficacy of switching from innovator infliximab to biosimilar inflixi- mab compared with continued

Protected

N/A

9
0
0
2022
UTÓSZÓ GYANÁNT a következőket kívánom megjegyezni.

évi püspöki látogatás jegyzőkönyvé- ben nem szereplő - főleg személyi - adatokat Chobot Ferenc: A Váci Egyház- megye Történeti Névtára két kötetéből vettem..

Protected

N/A

1
0
0
2022
Az ALK-pozitív tüdőrák korszerű diagnosztikája

06463922) from the dose­escalation component of a study in patients with advanced ALK+ or ROS1+ non­small cell lung cancer (NSCLC). Efficacy and safety of lorlatinib

Protected

N/A

11
0
0
2022
N Efficacy of Biologics Targeting Tumour Necrosis Factor-alpha, Interleukin-17 -12/23, -23 and Small Molecules Targeting JAK and PDE4 in the Treatment of Nail Psoriasis: A Network Meta-analysis

Efficacy and safety of guselkumab, an anti-inter- leukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe

Protected

N/A

7
0
0
2022
PhD Thesis – short version

The efficacy and safety of bevacizumab in addition to platinum- based chemotherapy for the first-line treatment of patients with advanced nonsquamous non-small-cell

Protected

N/A

20
0
0
2022

Töltsön fel további dokumentumokat, és töltse le azonnal az anyagtanulmányokat!